MedTrace Logo

APIDRA Registration Study

NCT00489190 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2009-03-16

No results posted yet for this study

Summary

To collect effectiveness and safety data during the treatment with Apidra glulisine (HMR1964) by means of subcutaneous injections to patients with Diabetes Mellitus 1st type during 12 weeks-active phase.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Insulin Glulisine

Sponsors & Collaborators

Principal Investigators

  • Arman UTEGULOV · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00489190 on ClinicalTrials.gov